RCMI Coordinating Center (RCMI CC) Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.
One or more keywords matched the following properties of Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.
PropertyValue
has major subject area list Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol, HDL; Hyperlipoproteinemia Type II; Kruppel-Like Transcription Factors; Liver; Perhexiline
information resource reference Guo Y, Fan Y, Zhang J, Lomberk GA, Zhou Z, Sun L, Mathison AJ, Garcia-Barrio MT, Zhang J, Zeng L, Li L, Pennathur S, Willer CJ, Rader DJ, Urrutia R, Chen YE. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest. 2015 Oct 01; 125(10):3819-30.
label Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.
Search Criteria
  • Apolipoprotein A I
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support